Compare ECX & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECX | PRTC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | China | United States |
| Employees | 1918 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 464.3M |
| IPO Year | N/A | N/A |
| Metric | ECX | PRTC |
|---|---|---|
| Price | $1.77 | $16.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 3.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $825.35 | N/A |
| Revenue Next Year | $35.50 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $13.30 |
| 52 Week High | $3.25 | $20.00 |
| Indicator | ECX | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 52.69 | 42.50 |
| Support Level | $1.57 | $16.60 |
| Resistance Level | $1.77 | $18.10 |
| Average True Range (ATR) | 0.16 | 0.43 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 76.18 | 19.02 |
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.